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1. Introduction 
Hematopoietic stem cells (HSCs) are a rare population of pluripotent cells that 
predominantly reside in the bone marrow. Under the appropriate microenvironmental cues, 
HSCs can undergo self-renewal, expansion, and differentiation into all types of progenitor 
and terminally differentiated blood cells required for survival of the host (Figure 1).  Due to 
the importance of this cell population for survival, protection of its genome from 
endogenous and exogenous genotoxic insults is a necessity. However, the intracellular 
molecular signaling network in hematopoietic cells that control surveillance of the genome 
as well as maintain genome stability is still largely unexplored. As more is learned 
regarding how these cells detect a genotoxic event and seek to repair the damaged 
nucleotides (i.e. DNA adducts), it will become even more feasible to design strategies to 
protect these life-sustaining cells when the host is exposed to a genotoxic event.   
Maintenance of genome stability in both the hematopoietic stem and progenitor cell (HSPC) 
populations is essential for the sustainment of normal hematopoiesis. For example, transient 
depletion of bone-marrow derived HSC induced by irradiation or chemotherapy can induce 
these primitive cells to expand so that the bone marrow can be fully reconstituted; blood-cell 
development can then continue with minimal disruption. However, once therapy-mediated 
DNA damage is too high, a DNA-damage threshold is reached resulting in subsequent cell 
death, myelosuppression, and if not treated, life-threatening bone-marrow failure (Figure 1). 
With the basal level of DNA repair relatively low in these cells, this does present a challenge 
to maintain normal hematopoiesis in individuals exposed to prolonged or high levels of 
genotoxic stress. The reduced ability to repair DNA damage in HSPCs that give rise to 
multiple mature blood-cell lineages can cause detrimental and long-lasting effects to the 
host resulting in abnormal cell function, cell death, cellular transformation, and eventually 
leukemogenesis (Figure 1). Numerous studies have shown that HSPCs are intrinsically more 
sensitive than other cell types and tissues mostly due to intrinsic limitations in DNA-repair 
capacity. Buschfort-Papewalis et al previously demonstrated that when human HSPCs  
(phenotypically defined as CD34+ cells) or differentiated cells (phenotypically defined as 
CD34- cells) from the same donor were exposed to alkylating agents, an overall decrease in 
repair capacity of the more primitive CD34+ cells compared the more differentiated cells 
CD34- cells was observed. When human CD34+ cells were exposed to a variety of 
chemotherapeutic drugs, single-strand DNA breaks as well as DNA adducts were found at 
higher levels and persisted for longer time periods than in CD34- cells (Buschfort-Papewalis 
et al., 2002), providing evidence that the kinetics of DNA repair are slower overall in the 
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CD34+ cells which is the most likely reason for their enhanced sensitivity to irradiation and 
chemotherapy. 
 
 
Fig. 1. Hematopoiesis and impact of genotoxic stress. Hematopoietic stem cells (HSCs) 
undergo self-renewal or differentiate into progenitor cells and ultimately into mature 
terminally differentiated blood cells. When HSC are exposed to exogenous genotoxic stress 
such as ionizing radiation or chemotherapy and intrinsic stress such as high levels of 
reactive oxygen species, the bone marrow can become myelosuppressed. If the stress if 
transient and not of high intensity, the HSC can repopulate the bone marrow. However, if 
the stress is of sufficient and prolonged intensity, a large number of cells will 
undergo apoptosis which will lead to bone marrow failure and potentially emergence of 
pre-leukemic cells (white cells).and ultimately transformation and full blown leukemia. 
In this chapter, an overview and analysis of investigations that employ in vitro and in vivo 
model systems to study how hematopoietic cells in mouse and man respond to genotoxic 
stress is presented. In addition, we summarize new therapeutic strategies designed to 
protect and limit therapy-induced stress to the hematopoietic system and the animal models 
used to develop and test these therapies. 
2. DNA repair pathways in hematopoietic stem and progenitor cells 
Mammalian cells are equipped to varying degrees with multiple DNA repair pathways in 
which to defend against the accumulation of DNA damage caused by environmental insults 
such as reactive oxygen species, ionizing irradiation, and chemotherapy. The DNA repair 
pathways- O6-methylguanine DNA methyltransferase (MGMT) direct repair, nucleotide-
excision repair, base-excision repair, mismatch repair, non-homologous DNA end-joining, 
and homologous recombination- all play prominent roles in maintaining genome stability. A 
brief overview of the major DNA repairs pathways that are operative in the vast majority of 
mammalian cells including hematopoietic stem and progenitor is presented below and 
detailed reviews of these pathways have been previously published (Bekker-Jensen & 
Mailand, 2010; Niedernhofer, 2008; Seita et al., 2010)  
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2.1 The direct repair protein O6-methylguanine DNA methyltransferase (MGMT) 
MGMT is also referred to as O6-methylguanine DNA methyltransferase and in contrast to 
the other DNA repair pathways which rely on a series of DNA repair proteins, acts singly 
to repair DNA damage caused by DNA adducts (Gerson, 2004). MGMT repairs DNA 
damage mediated by endogenous alkylation or by chloroethylating and methylating 
agents used in anti-cancer therapies. In a one-step stoichiometric reaction, MGMT 
removes adducts from the O6 position of guanine (Gerson, 2002). Each MGMT molecule 
repairs one O6 lesion; MGMT is then inactivated and degraded.  For chloroethylating 
agents such as carmustine (BCNU) and lomustine (CCNU), if lesions at the O6 position are 
not repaired by MGMT, an intramolecular rearrangement occurs over the next 18-24 
hours resulting in an interstrand crosslink with the paired cytosine on the opposite DNA 
strand (Sorrentino, 2002). Since this covalent crosslink between guanine and cytosine is 
poorly repaired, DNA replication is blocked and caspase 3-mediated apoptosis ensues. In 
regards to methylating agents such as temozolomide (TMZ), procarbazine, streptozotocin, 
and dacarbazine, formation of O6-methyl adducts disrupts hydrogen bonding between the 
methylated guanine and the corresponding cytosine. As DNA replication proceeds, O6-
methyl guanine pairs with thymidine instead of cytosine and this mismatch ultimately 
results in a guanine to adenine switch resulting in a point mutation.  As a result, the 
mismatch repair pathway is activated. During this repair process, single-strand gaps 
occur in the DNA and once this occurs in the same region on the opposite DNA strand, 
double-strand breaks occur. This leads to erroneous mismatch repair cycles and 
ultimately leads to apoptosis. Chloroethylating agents are far more potent than 
methylating agents in terms of cellular cytotoxicity. For chloroethylating agents, 
formation of only 5-10 O6-chloroethyl adducts per cell results in cell death. In contrast, for 
methylating agents, formation of approximately 6000 O6-methyl adducts per cell is 
required for cellular toxicity. 
MGMT is ubiquitously expressed in all tissues with the bone marrow express 
substantially lower levels(Sorrentino, 2002). The kinetics of MGMT regeneration following 
DNA repair also vary amongst tissues; MGMT expression in tumor cells regenerates 
relatively faster compared to normal tissues(Kreklau et al., 2001). The role of MGMT 
activity in repairing mutations that would otherwise lead to cancer is confirmed in studies 
using transgenic or knock-out mice. Indeed transgenic mice that overexpressed MGMT in 
the thymus were significantly less susceptible to thymic lymphomas caused by 
methylating agents compared to control littermates(Dumenco et al., 1993). MGMT knock-
out mice exhibited an increased incidence of tumors compared to wild-type mice 
(Glassner et al., 1999). These observations set the stage for developing strategies that can 
selectively protect normal tissues while simultaneously disrupting DNA repair in cancer 
cells. MGMT removes two kinds of alkyl adducts-O6-alkylguanine and O4 on thymine-
leaving behind an intact guanine or thymine in the DNA strand (Park & Gerson, 2005). 
The MGMT DNA repair protein is referred to as a “suicide” protein since after a single 
repair event, each molecule is ubiquitinated and ultimately degraded by the proteosome 
(Gerson, 2002, 2004). Inactivation of the MGMT gene via promoter methylation as well as 
over-expression of its gene product have been found in multiple types of cancer including 
glioma, melanoma, lymphoma, colorectal cancer and breast cancer and can lead to cell 
sensitivity or resistance to alkylators such as temozolomide, CCNU, and BCNU. Therefore 
establishing the expression level of MGMT expression in a particular cancer could help 
guide the selection of appropriate treatment modalities(Pegg, 2011).  
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2.2 Nucleotide excision repair (NER) 
NER is a type of repair in which a small series of nucleotide bases in each direction from the 
damaged DNA adduct are removed. There are two types of pathways associated with NER-
global genome and transcription-coupled repair-the specific pathway used depends on how 
the DNA damage is recognized (Park & Gerson, 2005). With global genome repair, 
xeroderma-pigmentosum complementation group C (XPC) and proteins recognize DNA 
damage. Many proteins are then recruited to remove the damaged bases as well as to repair 
the damage including XPA, RPA, transcription factor IIH, XPG, and polymerases delta or 
epsilon (Park & Gerson, 2005). With transcription-coupled NER, DNA damage leads to a 
halt in gene transcription and “sensor” proteins are rapidly recruited to the site for initiation 
of repair including MSH2, CSA, XBA2, XPB, XPG, BRCA1, and BRCA2 (Park & Gerson, 
2005). Defects in NER genes are the underlying cause of severe genetic disease states such as 
Xeroderma pigmentosum and Cockayne’s Syndrome.  
2.3 Base excision repair (BER) 
BER removes a misplaced or damaged base in the DNA strand. DNA glycosylases first 
remove a damaged base by creating an apurinic or apyrimidinic site within which AP 
endonuclease (APE-1) cuts the 5’ end of DNA so that the damaged base can be removed and 
replaced with the correct base. There are two pathways within BER which can be classified 
into “simple” and “complex.” The DNA glycosylases are different between the two 
pathways. In the simple pathway, N-methylpurine DNA glycosylase (MPG) removes a 
damaged site leaving an apurinic or apyrimidinic site without nicking the DNA 
backbone(Park & Gerson, 2005) . With the complex BER pathway, the DNA glycosylase such 
as 8-oxoguanine DNA glycosylase (OGG1) removes the damaged base and also nicks the 
DNA backbone(Park & Gerson, 2005). β-polymerase fills in the missing base and DNA 
ligase seals the nick in the DNA backbone completing BER(Limp-Foster & Kelley, 2000) . 
Interestingly, BER protein knockout mice are embryonic lethal which in contrast to NER, 
could explain why no known genetic diseases have been implicated with BER protein loss.  
2.4 Mismatch repair (MMR) pathway 
The MMR pathway recognizes single mismatches or misaligned sequence repeats (Belcheva 
et al., 2010; Martin et al., 2010). Msh2 will link with either Msh6 or Msh3 when recognized 
sequences are detected. Following detection, the Mlh1-Pms2 complex will coordinate the 
DNA endonuclease removal of damage, DNA re-synthesis, and ligation to complete the 
repair (Schmutte et al., 2001). Many diseases have been implicated in MMR deficiencies 
including lymphomas and stem-cell derived leukemias(Park & Gerson, 2005). 
2.5 Non-homologous DNA end-joining (NHEJ) 
Double strand breaks are most often repaired by NHEJ which can be caused by free radicals 
or ionizing radiation. Double-strand breaks can also occur following a malfunction during 
V(D)J recombination in T and B lymphocytes(Park & Gerson, 2005). This pathway is quite 
complex and uses does not always accurately repair the DNA which could be detrimental to 
the cell or in some situations such as during V(D)J recombination can add sequence 
diversity to genes encoding the T and B lymphocyte antigen-specific receptors.  The ends of 
the broken DNA strands are held by a protein complex comprised of Ku70, Ku80, and DNA-
PKcs. The repair is completed by XRCC4-DNA ligase IV (Lieber, 2010; Nick McElhinny et 
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al., 2000). Seita et al have demonstrated that in human HSPCs, that cycling status can dictate 
selection of the repair pathway that is operative. For example, in quiescent human HSPCs, 
the NHEJ pathway is preferentially used (Seita et al., 2010).  
2.6 Homologous recombination (HR) 
Homologous recombination (HR) can also repair double-strand breaks; however, it often can 
lead to further DNA damage with misalignments, deletions, and rearrangements. The PI-3 
kinase, ATM binds to the DNA following a double strand break acting to phosphorylate target 
proteins involved in repair including Mre11/Rad50/Nbs, BRCA1, BRCA2, RAD 51, BLM, and 
WRN(Park & Gerson, 2005). Abnormalities in homologous recombination are linked to many 
genetic diseases including Ataxia Telangiectasia, Werner’s syndrome and Bloom’s syndrome. 
In contrast to NHEJ, HR repair is generally considered superior in regards to ensuring that all 
DNA adducts are accurately repaired.   As discussed below, in the study by Seita et al, they 
find that cycling HSPCs in contrast to quiescent HSPCs, utilized the HR pathway to repair 
DNA strand breaks (Seita et al., 2010).  Abnormalities in nucleotide excision repair, telomere 
maintenance, or non-homologous DNA end-joining in mice have shown increased deficiencies 
in hematopoietic stem cells (HSCs) as they age implicating DNA damage as a driving force for 
stem-cell aging(Naka & Hirao, 2011). The continued research in employing gene therapy 
targeting increased DNA repair proteins in HSCs will continue to be an area of research as the 
limiting factor in anti-cancer treatments is normal tissue toxicity typically 
myelosuppression(Niedernhofer, 2008) and will be discussed in detail below. 
3. DNA damage responses in hematopoiesis 
Understanding the DNA-damage response and DNA-repair pathways that control the 
sensitivities of HSPCs to DNA-damaging agents will be key as the field continues to 
develop new pharmacological and cellular-based therapies to protect and maintain genome 
stability in these life-sustaining cells. The maintenance of HSC in a quiescent state in vivo is 
essential for long-term survival. Quiescence is widely considered to be an essential 
protective mechanism for stem cells that minimizes endogenous stress caused by cellular 
respiration and DNA replication. What molecular cues are essential for maintenance of 
“stem-ness” in vivo is a rapidly growing area of investigation and a complex network of 
proteins control the DNA-damage response and repair pathways. The tumor suppressor 
protein, p53, clearly plays a pivotal role in the regulation and promotion of senescence, 
apoptosis, and cell cycle arrest in a variety of cell types(Vousden & Lane, 2007). Several 
laboratories have utilized p53-deficient mice to investigate the role of this protein in 
hematopoiesis. Due to the dual functions of p53 in promoting survival versus cell death, 
results have been somewhat difficult to interpret. In transplantation studies, reconstitution 
of the bone marrow with p53-null murine HSC has resulted in increased, equivalent or 
decreased levels of engraftment in the mouse. Most likely, small nuances in experimental 
design are the most likely reason for these discrepancies and underscore the complexity of 
the p53-signaling network in hematopoiesis (Chen et al., 2008; Liu et al., 2009; Marusyk et 
al., 2010). In competitive repopulation assays, Dumble et al demonstrated that with 
increased p53 expression, HSCs exhibited decreased self-renewal capabilities (Dumble et al., 
2007). In murine studies by Liu et al(Liu & Gerson, 2006; Liu et al., 2009), p53 was highly 
expressed in primitive Lin− Sca-1+ c-Kit+ (LSK) wild-type cells compared to the more 
differentiated hematopoietic myeloid cells. The maintenance of LSK frequency appeared to 
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be dependent on p53 expression since LSK frequency of bone marrow cells derived from 
p53 -/- mice was significantly decreased. In vivo bromodeoxyuridine assays suggested that 
while p53 promoted HSC quiescence, p53 absence promoted entry of HSCs into cycle(Liu et 
al., 2009).  
The mechanisms by which HSPCs respond to DNA double-strand breaks (DSBs) induced by 
genotoxic stress, such as ionizing radiation (IR), is an emerging area of investigation. Two 
provocative studies conducted by Mohrin et al and Milyavsky et al studied IR-induced 
DNA damage responses of HSPC compartments derived from mice (Mohrin et al., 2010) and 
humans (Milyavsky et al., 2010) The molecular mechanisms by which murine and human 
HSPCs respond to IR appear to differ substantially(Seita et al., 2010). In the mouse model, 
Mohrin et al. found that murine HSPCs exposed to 2 Gy of IR were significantly more 
resistant than differentiated myeloid progenitors.  Furthermore, significant differences in the 
radiosensitivity of quiescent versus proliferating murine HSPCs were observed. The role of 
the ataxia telangiectasia mutated (ATM) protein in resistance to IR was also studied.  ATM is a 
serine-threonine protein kinase and a key sensor of DNA damage which is rapidly recruited 
to DNA double-strand breaks; upon activation at the strand break, ATM plays a major role 
in activation of the DNA-damage checkpoint.  In HSCs derived from ATM-null mice, 
quiescent and proliferating HSCs exhibited similar radiation sensitivities, indicating the 
importance of this protein in monitoring DNA damage in these populations. Further studies 
indicated that different modes of DNA repair are used to repair IR-induced DNA damage in 
quiescent versus cycling HSPCs. Quiescent HSPCs preferentially utilized the NHEJ 
pathway, which as mentioned previously is a fairly inefficient DNA repair pathway and is 
much more error prone than the HR pathway. High basal levels of NHEJ activity were 
detected in the quiescent HSPCs and this activity increased by ~2-fold following exposure to 
IR. In contrast to the quiescent HSPCs, the cycling HSPCs preferentially switched to the HR 
pathway to repair IR-induced double-strand breaks. The HR pathway is able to repair IR-
induced DNA damage more accurately than the NHEJ pathway. These data are consistent 
with the concept that cell-cycle status may influence the integrity of the DNA-repair 
processes and hence, influence long-term genome stability. For example, irradiated 
quiescent HSPCs gave rise to progeny that have genomic abnormalities at a higher 
frequency than cycling HSPCs. In particular when compared to non-irradiated resting 
HSPCs, greater than 30% of the cells derived from IR-treated resting HSPCs exhibited 
genomic rearrangements such as reciprocal translocations, interstitial deletions, and 
complex rearrangements. When mice were transplanted with non-irradiated or irradiated 
quiescent HSPCs (CD45.1+ cells) into CD45.2 lethally irradiated recipient mice, there was 
decreased engraftment in mice transplanted with the IR-treated versus non-treated HSPCs. 
While no transplanted mice developed leukemia or showed signs of abnormal 
hematopoiesis, further analyses demonstrated the presence of increased genome alterations 
in mice transplanted with IR-treated quiescent HSPC donor cells.  These data suggest a 
DNA-repair threshold exists in which repair of DNA damage in the mouse may not be fully 
accomplished in the quiescent HSPCs. Collectively, these findings also suggest that mouse 
HSC quiescence and reliance on NHEJ to repair IR may be an important mechanism 
contributing to mutagenesis at the stem-cell level.  (Mohrin et al., 2010) This may serve as 
the starting point for the emergence of certain blood-cell cancers. In addition, the 
accumulation of mutations in quiescent HSPCs over time may account for many of the stem-
cell based hematological abnormalities observed during aging. While the upside is that the 
quiescent state of murine HSPCs preserves these cells for use in the future, the downside is 
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that at least in mice, HSPCs in the quiescent state may be intrinsically more vulnerable to 
mutagenesis following DNA damage, particularly if the DNA damage pathways, such as 
NHEJ are operative and are not as reliable in repairing the DNA damage.  
Milyavsky et al. focused on the response of different hematopoietic cell populations  
isolated from human cord blood to IR-mediated DNA damage (Milyavsky et al., 2010). In 
contrast to the murine study, human HSPCs were found to have increased sensitivity to IR 
than the more differentiated progenitor cells. One likely reason for the increased sensitivity 
to IR was that the IR-mediated DNA damage led to slower repair of DNA damage in the 
human HSPC following IR exposure. In this study, Milyavsky et al determined the relative 
sensitivity of 3 human hematopoietic subpopulations isolated from cord blood and 
phenotypically defined as : (1) HSC- Lineage-negative (Lin-), CD34+CD38-  or Lin-
CD34+CD38-CD90+CD45RA- fraction; (2) myeloid progenitor population (MPP)-Lin-
CD34+CD38-CD90-CD45RA- population which contains fewer HSCs and many MPPs; (3) 
progenitor population-more mature progenitor/precursor cells, including CFCs, which are 
Lin-CD34+CD38+.  
To monitor the DNA damage and repair kinetics of the different hematopoietic cell 
populations, neutral comet assays and subnuclear foci of phosphorylated H2AX (γH2AX) 
were used as measures of IR-induced DNA double-strand breaks.  Different cell population 
were treated with 15 Gy IR and damage monitored at 30-60 minutes post-IR exposure. In the 
progenitor cells, 19.4% of the breaks were repaired by 30 minutes and 36.4% of the breaks 
had been repaired by 60 minutes. In contrast, in the more primitive population-HSC/MPP-
no repair of DNA-strand breaks was observed at 30 minutes post-IR; and at 60 minutes, 
29.9% of the breaks had been repaired.  The delay in repair of the double-strand DNA 
breaks indicated that the more quiescent HSC/MPP cells differed in their repair capacity 
from the differentiated progenitor population. Similar differences in DNA repair between 
the primitive and more differentiated cell populations were noted with the levels of γH2AX 
foci. At one hour post-exposure to IR, similar levels of γH2AX foci were evident in both the 
HSC/MPP and the progenitor populations. By 12 hours post-IR exposure, more γH2AX foci 
still remained in the HSC/MPP compared to the progenitor population (7.1 versus 2.7 
foci/nucleus respectively) further confirming the differential DNA repair capabilities of the 
two populations. Additionally these data correlated with decreased survival in the HSC 
versus the more differentiated progenitor cells in clonogenic assays. 
To assess the viability of irradiated HSPCs in the bone-marrow microenvironment, the SCID-
repopulating assay was used(Milyavsky et al., 2010). The nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice were transplanted with cord blood CD34+ cells and 5-10 
weeks post-transplant cohorts of mice received 3 Gy IR. The bone marrow was harvested from 
the mice 1.5 hours after IR delivery and the viability of the more primitive human HSC (Lin-
CD34+CD38-) versus the more differentiated (Lin-CD34+CD38+) was determined by flow 
cytometry.  The in vivo data correlated with the in vitro DNA damage and repair studies, for 
there was a 2-fold increase in IR-induced apoptosis in the more primitive Lin-CD34+CD38- 
versus the Lin-CD34+CD38+ cells. (Milyavsky et al., 2010) The authors went on to show that the 
primitive versus more differentiated hematopoietic cells utilize the p53/Bcl-2 pathway but to 
different degrees. Both in vitro and in vivo studies indicated that decreased p53 expression or 
over-expression of Bcl2 in cord blood progenitors blocked IR-induced apoptosis indicating the 
involvement of the p53-BCL2 pathway in regulating apoptosis and conferring some degree of 
radioprotection. However, in the secondary transplant setting, lack of p53 expression in the 
www.intechopen.com
 DNA Repair and Human Health 
 
426 
HSC resulted in higher levels of γH2AX foci in the engrafted cells and this correlated with 
decreased levels of engraftment. In contrast, in mice transplanted with the Bcl-2-
overexpressing HSCs, engraftment was within a normal range.  To begin to define in more 
detail, the intracellular proteins involved in regulating the DNA damage response to IR, global 
microarray expression profiling indicated that the apoptosis-stimulating protein of p53 
(ASPP1) was preferentially expressed and found to play a major role in mediating stem-cell 
radiosensitivity. ASPP1 is involved in the activation of p53-dependent apoptosis. Expression 
levels of ASPP1 were higher in HSC versus the more differentiated populations. The critical 
role of ASPP1 in response of primitive hematopoietic cells to IR was further confirmed in 
knockdown experiments; knockdown of ASPP1 in a CD34+CD90+ primitive cell population 
versus knockdown in a more differentiated CD34+CD90- cell population revealed that only in 
the primitive CDC34+CD90+ cells with decreased ASPP1 was there an increased resistance to 
IR exposure (Milyavsky et al., 2010). These studies clearly highlight the differences between 
these two species and underscore the importance of evaluating DNA damage responses in 
different models and cell types. It is becomingly increasing clear that DNA damage thresholds 
that dictate survival versus cell death do vary among different cell types and the mechanisms 
that regulate these responses will be different and need to be understood in order to develop 
relevant, effective, and safe strategies to protect bone marrow cells from genotoxic stresses. 
4. Increasing cell cycle arrest by pharmacological intervention to improve 
DNA-repair activity in hematopoietic cells exposed to genotoxic stress 
The use of growth-factor support such as granulocyte-colony stimulating factor, 
granulocyte/macrophage-colony stimulating factor, or erythropoietin can help increase the 
resistance to DNA-damaging agents and help facilitate recovery of the bone marrow 
following genotoxic therapy. However, these treatments are very expensive and can have 
adverse side effects. With the explosion of small-molecule development and drug discovery 
and as more is learned regarding how different cell types repair DNA damage, it may be 
possible to modulate DNA damage and repair pathways to increase protection and stability 
of the hematopoietic genome. These types of strategies could be used to prevent life-
threatening myelosuppression in the case of radiation accidents or disasters as well as an 
adjuvant to aggressive cancer therapies that typically induce severe myelosuppression or 
complete non-irreversible myeloablation.  In terms of IR exposure, the DNA double-strand 
DNA breaks caused by IR are cell-cycle dependent. The early G1 and late S phases are fairly 
resistant to IR effects, but the G1/S transition and the G2/M phases are the most sensitive to 
IR. It has been shown previously that extension of the G1 period following exposure to a 
genotoxic stress can enhance resistance; it is possible that this could allow for a longer 
period of time to repair the DNA before entering the cell cycle (Johnson et al., 2010). The 
cyclin-dependent kinases (CDK2, CDK4, and CDK6) are involved in promoting the G1 to S 
cell-cycle transition. Johnson et al demonstrated significant increases in the radioprotection 
of human cell lines and mice exposed to CDK4/6 small molecule inhibitors such as 
PD0332991(Pfizer, Inc.) that block entry into cell cycle.  If wild-type mice were treated with 
the selective inhibitors, a reversible cell-cycle arrest ensued in the most primitive HSPCs but 
not in cells already cycling the bone marrow or in other tissues (Johnson et al., 2010). The 
inhibitor-mediated inhibition of CDK4/6 function abrogated the total-body irradiation 
whether the inhibitor was given before or even up to several hours after delivery of total 
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body irradiation (TBI).  The authors also determined if inhibition of CDK4/6 could be used 
in the context of an anti-cancer therapy such as IR as to protect the mice from life-
threatening hematotoxicity but also to see if inhibition of CDK4/6 would have any impact 
on tumor–cell kill (Johnson et al., 2010). In a genetically engineered melanoma mouse 
model, male TyrRas Ink4a/Arf -/- develop autochthonous melanomas due to melanocyte-
specific promoter expression of mutant H-Ras. In this model, the growth of the tumors was 
not inhibited by CDK4/6 inhibitor treatment. When tumor-bearing mice were treated with 
7.5 Gy TBI, tumor growth slowed substantially for ~20 days. When the tumor-bearing mice 
were treated with 1 dose of the CDK4/6 inhibitor 4 hours before TBI, the tumors still 
responded to the irradiation and growth slowed as in control mice but also there was a 
substantial decrease in irradiation-induced myelosuppression and mortality. The relative 
contribution of a prolonged G1 arrest versus a block in the G1 to S transition in enhancing 
radioprotection of murine HSPCs is not completely clear.  Likewise, how these intriguing 
results will translate into the radioprotection of human bone-marrow cells and whether 
cancer-initiating mutations could permanently reside in the genome will require further 
investigation. 
5. Human gene-therapy clinical trials that target HSPCs-safety, efficacy, and 
vectors 
HSPCs have been studied for the past three decades as a relevant target for gene therapy 
due to feasibility with which they can be harvested, ex vivo manipulated, and transplanted 
back into the patient.  While the field of hematopoietic-stem cell gene therapy has had set 
backs and successes, many hurdles still remain in moving this from an experimental to a 
well accepted treatment modality. Investigations originally focused on utilization of 
retrovirus vectors for transduction of murine HSC(Williams et al., 1984). As studies 
progressed and investigators moved to humanized mouse models and large animal models, 
the promise shown in the murine transplant models did not always hold up. The first 
attempts of using a gene-therapy approach in human hematopoietic cells were also not very 
promising. Low-gene transfer and engraftment levels of genetically modified cells in 
humans were noted (Brenner et al., 1993b; Dunbar et al., 1995). Recent technical advances, 
however, including identification of  suitable cytokine cocktails that minimize stem-cell 
commitment and differentiation during ex vivo culture, use of Retronectin-enhanced gene 
transfer,  as well as enrichment of  stem and progenitor cells prior to transduction have 
improved the efficiency of gene transfer into human cells and resulted in substantial 
successes in  human gene-therapy trials particularly in X-SCID (Abonour et al., 2000; 
Cavazzana-Calvo et al., 2000) but also some unexpected abnormal events. In terms of the 
success of the trial, the selective advantage of the corrected hematopoietic cells in vivo 
clearly was a determining factor in generating sufficient numbers of corrected progenitors 
and lymphocytes in these patients. In spite of these improvements, however, the efficiency 
of gene transfer into primitive human hematopoietic cells and the engraftment of sufficient 
numbers of these transduced cells into patients still remains a major impediment. The very 
early gene-therapy trials using T-lymphocyte populations or hematopoietic 
stem/progenitor cells into subjects with adenosine deaminase deficiency associated with 
SCID revealed no signs of genotoxicity(Aiuti et al., 2009) . However, in the first trial of X-
SCID gene therapy, in which vector and transduction protocol were optimized,  the reality 
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that oncoretroviral-mediated insertional mutagenesis could serve as an initiator of leukemia 
in some patients transplanted with genetically engineered autologous hematopoietic cells is 
concerning. These early success stories coupled with the adverse events reported in the X-
SCID(Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 2003b) and chronic 
granulomatous disease (Metais & Dunbar, 2008; Ott et al., 2006)trials demonstrate that gene-
therapy based approaches have a place in the clinic, but at the same time, more research into 
all aspects of these approaches and the disease state to be treated require more investigation.   
When the first cases of insertional mutagenesis were reported in the X-SCID trials, the 
community responded in a very positive and aggressive way to unravel the underlying 
cause of the T-cell leukemia in several of X-SCID patients. Retroviral insertion into the 
genome near the LMO-2 and other growth-promoting loci in the transplanted hematopoietic 
cells was defined very early after the adverse events were reported. In addition, as 
preclinical studies in nonhuman primates, dogs, and mice have progressed over the past 
decade, development of leukemias most likely linked or initiated by vector-mediated 
insertional mutagenesis have been reported in these animal models(Li et al., 2005; Li et al., 
2002; Modlich et al., 2005; Nienhuis et al., 2006; Seggewiss et al., 2006; Zhang et al., 2008). 
Since these reports, a large effort has focused on designing vectors with better safety 
profiles, well-defined transduction protocols, as well as improved small and large animal 
models for long-term evaluation of efficacy and safety testing. As the field of hematopoietic 
gene therapy continues to progress, it is highly likely that vector design coupled with 
optimal transduction protocols and better understanding of the underlying hematological 
disease will result in cures (Trobridge et al., 2005).  
5.1 Retroviral vectors  
Many improvements in vector design resulting in improved transgene expression and safe 
guards against generation of replication-competent viruses have been summarized in detail 
elsewhere(Trobridge, 2011; Yi et al., 2011). A brief summary of retroviral vector types and 
transduction considerations are discussed below.  
5.1.1 Gamma-retroviral vectors  
Gamma-retroviral vectors were the first to be used for the purpose of marking murine 
hematopoietic stem and progenitor cells (Williams et al., 1984). Due to their long history in 
development, they have been the most commonly used so far as vectors for clinical studies.  
It has been widely appreciated for some time now, that cell division of the retrovirally 
transduced cells is essential for stable integration of gamma-retroviral vectors into the host 
genome (Lewis & Emerman, 1994; Miller et al., 1990). Due to the highly quiescent nature of 
the hematopoietic cells, cytokines that promote cell division in primitive hematopoietic cells 
have been utilized over the years and in combination with Retronectin-coated plates-to 
enhance proximity of retroviral particles and cells-have resulted in fairly high levels of 
transfer into hematopoietic stem and progenitor cells derived from mice, canines and 
primates(Horn et al., 2002b; Kiem et al., 1999; Kurre et al., 2002; Rosenzweig et al., 1999).  
There are generally 3 disadvantages in using a gamma-retroviral vector to transduce 
hematopoietic cells. Silencing of the transgene expressed by the gamma-retroviral vectors 
can occur over time and this has been well documented in murine transplant studies 
(Halene et al., 1999; Klug et al., 2000; Robbins et al., 1998).  Additionally, while gene transfer 
into primitive hematopoietic cells is fairly efficient, the cytokine-mediated entry into cell 
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cycle ex vivo can lead to a loss or primitive hematopoietic cells residing in the graft, which 
could compromise engraftment kinetics (Tisdale et al., 1998). The final downside of gamma-
retroviral vectors is their preferential integration near transcript start sites(Wu et al., 2003), 
which in the proper molecular context can increase the chances of insertional mutagenesis 
and development of leukemia as discussed above.   Alternative vector systems such as 
lentiviral or foamy viral vectors, are being investigated in a variety of contexts and may 
have better integration properties such that only minimal cytokine exposure and ex vivo 
culture time are required to achieve acceptable gene transfer into repopulating 
hematopoietic stem and progenitor cells (Horn et al., 2004a; Josephson et al., 2002; Miyoshi 
et al., 1999; Trobridge et al., 2005).  
5.1.2 Lentiviral vectors 
Lentiviral vectors do not necessarily require mitosis in order to enter the nucleus and 
integrate into the genome. This vector system has been shown to successfully transduce a 
variety of nondividing target cells(Case et al., 1999; Naldini et al., 1996; Reiser et al., 1996). 
However, lentiviral-mediated transduction was relatively higher still, when the target cells 
were induced to undergo cell division during the transduction period (Naldini et al., 1996; 
Russell & Miller, 1996; Trobridge & Russell, 2004). Lentiviral vectors can also efficiently 
transduce SCID-repopulating cells in the NOD/SCID mouse model(Miyoshi et al., 1999), as 
well as long-term repopulating cells in canines (Horn et al., 2004b) and monkeys(An et al., 
2001; An et al., 2000; Horn et al., 2002a).  
As more long-term repopulation studies are completed, it is becoming clear that lentiviral 
vectors in contrast to gamma-retroviral vectors allow for efficient transduction, optimal 
reconstitution, and quicker recovery following transplantation (Goerner et al., 1999; Goerner 
et al., 2001; Horn et al., 2002a). It is possible that lentiviral vectors can transduce larger 
numbers of immature hematopoietic repopulating cell compared to gamma-retroviral 
vectors. One obstacle to extending these observations to large animal models is that human 
immunodeficiency virus type 1 (HIV1)-based lentiviral vectors in nonhuman primates  
have a low transduction rate in Old World monkey cells(Song et al., 2005; Stremlau  
et al., 2004; Stremlau et al., 2005).  Peter-Kiem and colleagues have found, however, that 
human and pigtail macaque (Macaca nemestrina) but not baboon (Papio cynocephalus anubis) 
CD34+ cells could be efficiently transduced with lentiviral vectors (Beard et al., 2007; 
Trobridge et al., 2005).  
5.1.3 Foamy virus vectors 
Foamy (spuma) retroviral vectors are the newest vector system to undergo extensive 
development and testing for use as a gene-transfer vector for HSC gene therapy.  The vector 
backbones clearly possess several characteristics that make this vector attractive for gene 
transfer into primitive hematopoietic cell lineages.  The vector has the ability to allow for 
subcloning of larger therapeutic transgenes than the other vector systems. Importantly for 
use in the clinic, the foamy virus does not cause any known pathogenesis in humans which 
further strengthens the safety of this novel viral vector (Trobridge et al., 2002). Foamy viral 
vectors require mitosis for integration into the host genome. In contrast to gamma-retroviral 
and lentiviral vectors, foamy vectors can form a stable intermediate in quiescent 
cells(Trobridge & Russell, 2004) which can exist for days. Therefore, this allows for increased 
opportunities for the foamy viral intermediate to integrate into the genome of the 
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transduced cell once it divides at a later time point, presumably even after it is transplanted. 
This is possibly one reason why foamy viral vectors have shown promise in the 
transduction of SCID-repopulating cells derived from quiescent mobilized peripheral blood 
(Josephson et al., 2004). How well lentiviral versus foamy viral vectors can transduce canine 
hematopoietic stem and progenitor cells has been investigated.  Equivalent levels of gene 
transfer were evident in both myeloid and lymphocyte lineages (Beard & Kiem, 2009). 
Interestingly, when the retroviral insertion sites of lentiviruses and foamy viruses were 
compared, different insertion profiles was found between the two viral vectors. (De Palma 
et al., 2005; Dunbar, 2005; Hematti et al., 2004; Laufs et al., 2004; Nowrouzi et al., 2006; 
Trobridge et al., 2006). Lentiviral vectors integrated more frequently within the coding 
region of genes compared to gamma-retroviruses which exhibited a strong preference for 
the 5′ end of genes most often near the enhancer/promoter regions. Another attractive 
feature of the foamy vectors is that they do not preferentially integrate  near transcript start 
sites, which would predict there is less likely chance of activating near-by gene expression 
(Trobridge et al., 2005). Investigations continue to interrogate if the genome-insertion profile 
of lentiviral vectors will result in any difference in the potential mutagenic properties of 
these vector systems(Modlich et al., 2006; Montini et al., 2006).   
5.2 Viral envelopes for pseudotyping vectors 
Selection of an appropriate viral envelope for pseudotyping a particular vector is critical and 
can influence the transduction efficiency and engraftment capability of the target 
population. For example, if the levels of the host receptor that is specific for the viral 
envelope is high, then optimal levels of gene transfer can be expected (Kurre et al., 1999; 
Kurre et al., 2001b; Orlic et al., 1996; Sabatino et al., 1997). Gamma retroviral vectors were 
originally pseudotyped with the amphotropic envelope in human ((Brenner et al., 1993a; 
Dunbar et al., 1995; Kohn et al., 1995)and nonhuman primate (Bodine et al., 1993; van 
Beusechem et al., 1992). As studies progressed, it was discovered that hematopoietic cells in 
general have low levels of the amphotropic receptor on the most primitive hematopoietic 
cells; thus, providing a reason for the low levels of gene transfer into the primitive 
hematopoietic cells(Orlic et al., 1996).  Other viral envelope glycoproteins have been 
discovered and tested(Akkina et al., 1996; Cone & Mulligan, 1984); these include the gibbon 
ape leukemia virus (GALV) envelope(Wilson et al., 1989), the feline endogenous retrovirus 
(RD114) envelope(Porter et al., 1996), and the vesicular stomatitis virus G glycoprotein 
(VSVG) envelope(Emi et al., 1991). When GALV- versus amphotropic-pseudotyped gamma-
retroviral vectors were compared, GALV-pseudotyped vectors had higher marking than 
vectors with amphotropic envelopes in both human progenitors(von Kalle et al., 1994) and 
baboon repopulating cells(Kiem et al., 1999). The VSVG envelope has undergone extensive 
testing and has been attractive to the community since it can be substantially concentrated 
via ultracentrifugation to increase viral titers (Burns et al., 1993). Establishing stable 
packaging lines that also provide high titer has been problematic since the VSVG can be 
toxic to the packaging cells(Yang et al., 1995; Yee et al., 1994).  The RD114 envelope has some 
advantages in that it is not toxic, and due to its stability, viral titers can be increased by 
ultracentrifugation. The RD114 envelope is also resistant to inactivation by human and 
macaque sera(Kelly et al., 2001; Sandrin et al., 2002). The disadvantage of this envelope, is 
that transduction efficiencies into human hematopoietic cells is variable and is due to 
differing levels of RD114 receptor expression on the human cells(Green et al., 2004).  
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5.3 Optimal conditions for retroviral-mediated transduction of HSPCs 
The development of an optimal cytokine cocktail for retroviral transduction of primitive 
hematopoietic cells has been challenging. To optimize gene transfer into quiescent HSCs, the 
cytokine combination needs to promote entry into cell cycle but at the same time provide a 
cytokine milieu that minimizes differentiation, maintains the ability of the cells to engraft 
efficiently in the host and still undergo self renewal. A number of cytokine cocktails have 
promoted reasonable levels of gene transfer. (Dunbar et al., 1996; Hematti et al., 2004; Horn 
et al., 2002b; Kiem et al., 1998; Kiem et al., 1997a; Kiem et al., 2002; Kurre et al., 2001a; 
Tisdale et al., 1998; Wu et al., 2000). For example, 72 hr to 96 hr transduction periods for 
gamma-retroviral transductions and 18 hr to 24hr for lentiviral and foamy virus 
transductions has yielded reasonable levels of gene marking in vitro and in vivo.  The 
immobilization of the fibronectin fragment, Retronectin (originally referred to as CH-296) on 
plates prior to transduction improves transduction efficiencies of numerous cell types 
(Donahue et al., 2001; Hanenberg et al., 1996; Kiem et al., 1998; Vassilopoulos et al., 2001; Wu 
et al., 2000) by co-localizing VLA-4+ and/or VLA-5+ target cells and viral particles on the 
plates, and in addition, via integrin-mediated signaling, promotes survival and improves 
stem-cell engraftment (Dao et al., 1998; Donahue et al., 2001).  
6. Expression of drug-resistance genes in HSPCs  
A strategy for protecting HSPCs from genotoxic stress caused by alkylator therapy is to 
overexpress DNA-repair proteins in these cells. As long as expression levels of the DNA 
repair protein are adequate during the treatment phase, this is an attractive approach since 
the DNA damage caused by the therapy could be adequately repaired in the hematopoietic 
cells. Depending on the doses of therapy used, one could use alkylators to preferentially 
expand transduced versus non-transduced cells, or if the treatment is an actual cancer 
therapy which would need to be administered at higher levels and more frequently, this 
approach could be used to kill cancer cells and protect the highly susceptible bone-marrow 
cells from the therapy. 
In terms of utilizing a gene-therapy approach to serve as a chemoprotectant of the HSPCs, 
there are three central questions regarding the introduction of genes into hematopoietic cells 
that render them resistant to chemotherapy. First, is it possible for genetically modified cells 
to be amplified in vivo and still maintain self-renewal capacity? Second, is sufficient and 
sustained expression of the chemotherapy-resistant gene obtained so that low dose-induced 
selection of transduced cells or bone-marrow toxicity typically associated with intensive 
cancer chemotherapy can be significantly reduced? Third, will hematopoiesis proceed in a 
normal manner in the post-chemotherapy recovery period? There is a theoretical concern 
that HSC depletion or exhaustion may ensue. In this case, small numbers of transduced 
stem cells would be pushed to preferentially expand and differentiate on a continuous basis. 
Although self-renewal would be presumably be an integral part of this process, overtime 
preferential differentiation beyond normal hematopoietic limits may lead to extinction of the 
transduced stem-cell pool(Pollok, 2003).  The expression of chemoprotective gene products 
such as the multidrug resistance protein (MDR1)(Abonour et al., 2000; Hanania et al., 1995; 
Hesdorffer et al., 1998; Hildinger et al., 1998; Schiedlmeier et al., 2000), dihydrofolate 
reductase (DHFR) (Allay et al., 1998; Brenner et al., 1993b; Corey et al., 1990; Persons et al., 
2004; Warlick et al., 2002; Williams et al., 1987), cytidine deaminase gene(Beausejour et al., 
2001; Eliopoulos et al., 2002; Momparler et al., 1996; Rattmann et al., 2006) and MGMT (Cai 
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et al., 2008; Cai et al., 2006; Cai et al., 2011; Cai et al., 2005; Chinnasamy et al., 1998b; Davis et 
al., 2000; Davis et al., 1999; Hickson et al., 1998; Jansen et al., 2001; Jansen et al., 2002; Moritz 
et al., 1995; Neff et al., 2003; Ragg et al., 2000; Sawai et al., 2001) have been thoroughly 
investigated as potential candidates to protect hematopoietic cells residing in the bone 
marrow. A number of retroviral vectors derived from gamma-retroviruses, lentiviruses, and 
foamy viruses as described above continue to be tested for delivery of drug-resistance genes 
to primitive hematopoietic cells.  
7. In vivo selection and protection of chemoresistant HSPCs  
Studies using small and large animal models continue to investigate the consequences and 
potential of using genotoxic stress to select in vivo for retrovirally transduced HSPCs. A 
powerful tool for in-vivo selection of HSPCs is overexpression of a mutant form of the 
MGMT DNA repair protein, MGMTP140K, which is resistant to the MGMT inhibitor, O6-
benzylguanine (O6-BG) (Figure 2). Overexpression of MGMTP140K in HSC derived from  
mice, canines, nonhuman primates, and humanized xenograft models, shows promise as a 
an approach for selection and protection of the MGMTP140K-transduced HSPCs following 
administration of O6-BG in combination with alkylators such as BCNU, CCNU, or TMZ 
(Gerson, 2002).  
If MGMTP140K expression is adequate in the HSC, it should also protect the HSPC from high-
dose alkylator therapy required in some cancer treatments and thereby prevent therapy-
induced myelotoxicity (Figure 3).  Generation of HSPC that efficiently repair DNA damage 
due to chemotherapy may protect patients from life-threatening cytopenias commonly 
observed following dose-intensified therapy. A case in point, in recent phase II clinical trials, 
patients with nitrosourea-resistant gliomas were simultaneously treated with O6-BG to 
deplete MGMT in the cancer cells, followed by treatment with the DNA-damaging agents, 
BCNU or temozolomide(Quinn et al., 2009; Quinn et al., 2002). Although lack of tumor 
progression was transiently observed in some patients, effective dose-escalation therapy 
could not be achieved due to severe hematopoietic toxicity. These studies provide clinical 
proof that strategies protecting HSC during dose-intensified therapy are indeed clearly 
needed in relapsed patients requiring high-dose alkylator therapy. There are two ways in 
which expression of a chemoresistant gene such as an MGMT could be used for 
hematopoietic gene therapy (Figure 4). First, cells transduced with an oncoretrovirus vector 
that co-expresses the MGMT mutant gene as well as another therapeutic gene that does not 
otherwise have a selective proliferative advantage could be selected or enriched for in vivo. 
In this situation, selection of transduced cells using a low-dose chemotherapeutic regimen 
would be desirable so as not to cause unnecessary alkylator-mediated DNA damage to other 
tissues.  However, the requirement for alkylators which are highly genotoxic and potentially 
mutagenic, has dampened enthusiasm for using overexpression of MGMT mutant proteins 
as an in vivo-selection tool. Second, as mentioned above, expression of the MGMT mutant 
would be utilized as a means of protecting hematopoietic cells from high-dose alkylator 
therapy designed to kill tumor cells. In the cancer patient setting, the use of MGMT to 
actually protect the hematopoietic cells from alkylator-based regimens used to treat cancers, 
such as glioblastoma and melanoma is a reasonable and clinically appropriate use of this 
chemoprotective mechanism. The use of bicistronic oncoretrovirus vectors that co-express 
MGMT mutant proteins and the enhanced green fluorescent protein (EGFP) have aided in 
the evaluation of in vivo selection of transduced hematopoietic cells (Figure 4).  
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Fig. 2. Creation of chemoresistant HSPCs by expression of a mutant MGMT protein.  
HSPCs are transduced with a retroviral vector that encodes for a mutant MGMT protein 
such as MGMTP140K. If expression levels of the MGMTP140K transgene are sufficient and 
sustained, then the transduced cells will be able to repair the DNA damage caused by 
alkylators such as BCNU and TMZ. Nontransduced HSPCs will only express wild-type 
MGMT and therefore will not survive since wild-type activity will be inhibited by the 
MGMT inhibitor, O6-benzylguanine (O6-BG). While many mutant MGMT molecules have 
been tested, the MGMTP140K has shown the most consistency in terms of in vivo selection in a 
variety of animal models. 
 
 
Fig. 3. Increased tumor-cell killing by sensitizing tumor cells to standard-of-care alkylator 
therapy. When tumor cells are exposed to MGMT inhibitors such as O6-BG, wild-type 
MGMT is irreversibly inhibited. However, de novo synthesis of MGMT is not blocked and 
will continue. Therefore, a series of bolus injections or continuous infusion of the MGMT 
inhibitor may be necessary to sufficiently inhibit MGMT-mediated DNA repair protein. If 
MGMT inhibition is complete, subsequent exposure to alkylators such as BCNU or TMZ 
will lead to sustained levels of DNA damage and cell death. 
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Fig. 4. In vivo selection of MGMTP140K-EGFP-transduced hematopoietic cells. The 
enhanced green fluorescent protein (EGFP) has been used in a number of in vivo studies to 
follow the selection and emergence of MGMTP140K-positive cells. In a successful in vivo-
selection protocol, EGFP-positive cells (green cells) increase over time in multiple 
hematopoietic lineages following exposure to O6-BG/BCNU or O6-BG/TMZ. 
Several groups have evaluated the efficacy of chemoprotection using different mutant forms 
of MGMT that are highly resistant to O6-BG  (Davis et al., 2000; Pollok, 2003; Ragg et al., 
2000; Sawai et al., 2001). Ragg et al compared efficacy of in vivo selection using MGMT-
P140A, P140K, and wild-type MGMT. This study showed that MGMTP140K expression 
resulted in improved protection of the bone-marrow HSCs from an O6-BG/BCNU 
chemotherapy regimen compared to the MGMTP140A mutant or wild-type MGMT(Ragg et 
al., 2000). When compared to wild-type MGMT, the MGMTP140A mutant was 40-fold more 
resistant to O6-BG and the MGMTP140K mutant was 1000-fold more resistant. These data 
support the hypothesis that the combination therapy of O6-BG/BCNU effectively selects for 
higher numbers of murine HSC cells compared to BCNU treatment alone and that partial 
selection with BCNU was presumably due to survival of transduced differentiated 
progenitors, but inefficient selection of MGMTP140K-transduced stem cells. This hypothesis 
was confirmed in secondary transplants studies.   
TMZ continues to be intensely studied as an alternative to BCNU and may have several 
advantages over BCNU in terms of DNA repair and multi-organ toxicity. Myelosuppression 
is the primary toxicity associated with TMZ therapy and pulmonary and renal toxicity is 
less often observed. Therefore, it has been proposed that dose-intensified therapy to 
effectively kill tumors with high levels of MGMT may be more feasible with a combination 
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of O6-BG and TMZ in contrast to O6-BG and BCNU. Reese et al demonstrated in vitro that 
murine and human clonogenic cells were indeed protected from O6-BG and TMZ by 
expression of MGMTG156A and were also protected to a significantly higher degree than a 
SW40 colon cancer line that expresses high levels of MGMT(Reese et al., 1999). Sawai et al 
demonstrated effective protection and sequential selection of murine stem cells in vivo by 
expression of MGMTP140K and repeated cycles of O6-BG and TMZ(Sawai et al., 2001).  
Koc et al treated mice with nonmyeloablative doses of O6-BG and BCNU and transplanted 
cohorts of mice with MGMTG156A-transduced bone marrow cells(Koc et al., 1999). 
Subsequently, mice were inoculated with SW480 colon cancer cells that express high levels 
of wild-type MGMT. In contrast to control mice, there was a 9-fold increase in resistance of 
clonogenic cells to BCNU and tumor growth was significantly delayed in tumor-bearing 
mice following multiple cycles of O6-BG/BCNU. These studies indicated that marrow 
protection from high-dose chemotherapy and simultaneous decline in tumor growth was 
feasible even using a tumor that is resistant to standard alkylator therapy.  
7.1 Disadvantages of murine transplantation models for assessing utility of transgene 
over-expression in HSPCs  
The use of murine stem-cell transplantation modeling clearly set a solid foundation on 
which to initially determine the promise of genetically modifying long-term repopulating 
stem cells and helped move the field of hematopoietic gene therapy forward (Dick et al., 
1985; Keller et al., 1985; Williams et al., 1984). Yet, inter-species differences between mice 
and humans do need to be taken into consideration as the field evaluates feasibility gene-
therapy approaches for the clinic. The life span of mice is shorter compared to humans and 
the high gene-transfer levels obtained in murine HSCs has not been obtainable in human 
clinical trials. This could be due to relative levels of receptors on mouse versus human 
hematopoietic cells. For example, transduction of murine hematopoietic progenitor cells 
with murine ecotropic envelope pseudotyped gamma-retroviral vectors  was highly efficient  
(Dick et al., 1985). In contrast, transduction of canine and human progenitors with a gamma-
retroviral vector pseudotyped with the amphotropic envelope used in clinical trials was 
much less efficient than transduction of mouse progenitors with the ecotropic 
envelope(Brenner et al., 1993a; Stead et al., 1988). This was due at least in part to low levels 
of the amphotropic receptor on human hematopoietic stem and progenitor cells (Orlic et al., 
1996). A variety of inter-species differences can dictate the transduction efficiency of 
primitive hematopoietic cells in mice and man including differences in cell-cycle status, 
telomerase activity, and repopulation capacity of the hematopoietic stem cells (Abkowitz et 
al., 1996; Abkowitz et al., 1995; Cheshier et al., 1999; Guttorp et al., 1990; Miller et al., 1996; 
Naldini et al., 1996; Shepherd et al., 2007; Trobridge & Russell, 2004; Trobridge & Kiem, 
2010). For example, in mice, a single HSC is capable of engrafting and reconstituting the 
entire murine hematopoietic system (Dick et al., 1985; Osawa et al., 1996). Additionally, 
sources of the hematopoietic cells could yield conflicting results; for mouse studies, Lin−, 
Sca-1+, c-kit+ (LSK) or bone-marrow derived from 5-flurouracil-treated mice are used in 
contrast to human CD34+ cells that are the target cell population for the SCID-repopulating 
assay and for human gene therapy trials (Drew et al., 2002; Okuno et al., 2002). In contrast, 
except for studies using pre-leukemic or leukemic cells, the reconstitution capacity of HSCs 
in non-human primates and dogs appears to always be derived from polyclonal populations 
of HSCs. Importantly, in studies evaluating the in vivo safety profiles of  gene-transfer 
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vectors, mouse cells tend to be more easily transformed than human cells, which could 
complicate decisions regarding the utility of new gene-therapy strategies(Hahn et al., 1999; 
Hahn & Weinberg, 2002; Land et al., 1983) The ease of transforming murine cells could also 
over-estimate the likelihood of an adverse mutagenic event and hence, not provide a 
realistic simulation of what to expect in human gene-therapy trials. 
The long-term outcome of MGMTP140K expression in conjunction with extended alkylator 
dosing is a critical variable in assessing the safety of this approach and the potential for 
mutagenic events due to incomplete repair of DNA adducts. Recently, the long-term effect 
of MGMTP140K-mediated DNA repair and the possibility for emergence of leukemic cells was 
followed in a murine serial bone-marrow transplant model;  the clonality of hematopoiesis 
in animals transplanted with in vivo selected MGMTP140K-expressing cells was followed all 
the way through tertiary transplant recipients(Giordano et al., 2011). In this study, a gamma-
retroviral MGMTP140K-IRES-EGFP vector was utilized and the target cells were from 5-
fluorouracil-treated C57Bl/6 mice.  At approximately one month post-transplantation,  
weekly cycles of alkylator therapy were administered for 5 weeks and consisted  of 
25 mg/kg  O6-BG  followed 1 hour later by injection of either  BCNU, 10 mg/kg , ACNU, 
6 mg/kg, or  TMZ, 70 mg/kg and followed over time. In secondary and tertiary recipients, 
mice received four weekly treatment doses.  The bone-marrow cells were subsequently 
analyzed for selection of MGMTP140K+ cells and for proviral insertion sites at 3–5 weeks 
following the last cycle of chemotherapy. Due to the repetitive doses of therapy, all cohorts 
had levels of MGMTP140K-transduced cells that approached 100%.  While polyclonal 
reconstitution could be found in three primary, one secondary, and three out of four tertiary 
transplant recipients analyzed,  monoclonal or biclonal integration patterns were observed 
in most 2° or 3° recipients with insertions found in intron 1 of the Usp10 gene or 
downstream of the Tubb3 gene, respectively.  The administration of high- versus low-dose 
alkylator therapy could also dictate the clonality of the in vivo-selected transduced cells. In 
earlier studies, the selection of MGMTP140K-transduced hematopoietic cells using low doses 
of chemotherapy allowed for the preservation of polyclonal hematopoiesis (Ball et al., 2007; 
Beard et al., 2009; Gerull et al., 2007). However, the outcome of myeloablative dose of 
therapy in large animal models still needs to be investigated. 
7.2 In vivo selection of HSPCs in humanized mouse models 
With the development of immunodeficient mouse strains, such as the nonobese 
diabetic/severe combined immunodeficiency mouse (NOD/SCID), human hematopoiesis 
can be established and gene-therapy strategies targeting primitive human CD34+ cells can be 
evaluated. (Ishikawa et al., 2005; Ohbo et al., 1996). Human hematopoietic cells that home 
and engraft in the bone marrow of the NOD/SCID mouse are called SCID-repopulating 
cells (SRC). These cells proliferate and undergo multi-lineage differentiation(Kamel-Reid & 
Dick, 1988; Larochelle et al., 1996; Lee et al., 2001; Wang et al., 1997; Wang et al., 1998).The 
NOD/SCID xenograft model has been used to study selection and protection of human 
cells. Although efficient transfer of genes into SRC derived from umbilical cord blood CD34+ 
cells has been demonstrated(Conneally et al., 1997; Conneally et al., 1998; Demaison et al., 
2000; Hennemann et al., 1999; Kelley et al., 2000; Marandin et al., 1998; van Beusechem et al., 
1992), we reported that retrovirus-mediated gene transfer into SRC derived from G-CSF-
mobilized peripheral blood was markedly less efficient(Pollok et al., 2001). With this in 
mind, we previously tested to what extent small numbers of transduced G-CSF-mobilized 
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peripheral blood CD34+ cells could be  in vivo selected by expression of the P140K mutant 
and administration of O6-BG/BCNU.  Our laboratory demonstrated effective in vivo 
selection of primitive human hematopoietic cells in NOD/SCID mice following injection of 
O6-BG/BCNU.  Up to 100% of human cells derived from umbilical cord blood or G-CSF-
mobilized peripheral blood were resistant to O6-BG/BCNU treatment. Nonlethal doses of 
chemotherapy, consisting of 20 mg/kg O6-BG and 5 mg/kg BCNU, were used and resulted 
in only mild cytopenia in the NOD/SCID mice. MGMTP140K-transduced cells underwent 
multi-lineage differentiation in vivo and hematopoietic cells were present after in vivo 
treatment that possessed clonogenic activity and expressed high levels of the MGMTP140K 
activity (Cai et al., 2006). 
In regards to assessing whether HSPCs can be protected from a chemotherapy regimen used 
to kill cancer cells, a combination therapy consisting of an O6-BG double bolus and BCNU 
has been studied by us and others. Kreklau et al showed significant regeneration of wild-
type MGMT activity in tumors 24 hours post-O6-BG injection(Kreklau et al., 2001). For 
optimal numbers of covalent crosslinks between guanine and cytosine to form, it is highly 
desirable that MGMT activity be kept to a minimum during the first 24 hours following 
alkylator therapy. Therefore a high-dose chemotherapy regimen consisting of an O6-BG 
double-bolus injection (30 mg/kg followed by 15 mg/kg 8 hours later) and BCNU (10 
mg/kg, administered one hour after first O6-BG dose) that efficiently inhibits wild-type 
MGMT in tumor cells for 24 hours was utilized. Using NOD/SCID mice transplanted with 
MGMTP140K-selected murine bone marrow cells and engrafted with a human glioma, SF767, 
that expresses high levels of wild-type MGMT, we demonstrated significant regression of a 
human glioma(Kreklau et al., 2003). 
Utilization of the NOD/SCID xenograft as a model to study in vivo selection and protection 
of human HSPCs during chemotherapy provides a useful model for testing new vector 
designs for expression of chemoresistant genes and evaluating the effect of ex vivo 
manipulation of stem and progenitor cells on hematopoiesis in vivo. Development of 
strategies to protect larger numbers of primitive clonogenic cells is needed. HSCs derived 
from adult sources can be nonresponsive to cytokine stimulation that is needed for 
integration of oncoretrovirus vectors into the host genome(Veena et al., 1998) . In addition, 
adult HSCs lose their pluripotency due to cytokine-mediated differentiation (Gothot et al., 
1998; Guenechea et al., 1999). One promising alternative to protect larger numbers of stem 
cells is to use other virus vectors such as lentivirus or foamy virus that are reported to more 
efficiently transduce nondividing stem cells. Zielske and Gerson demonstrated significant 
protection of human clonogenic cells in vitro using a lentivirus vector that expresses the 
MGMTG156A mutant (Zielske & Gerson, 2002).   
Repetitive low-dose treatment for in vivo selection of MGMTP140K-transduced cells has been 
successful in mice and large animal models. (Beard et al., 2010; Neff et al., 2005) Numerous 
transplant studies have convincingly proven that long-term repopulating murine HSCs 
could be selected in vivo with O6-BG/BCNU, O6-BG /TMZ, or O6-BG /CCNU. (Cai et al., 
2008; Davis et al., 2004; Jansen et al., 2002; Kreklau et al., 2003; Milsom et al., 2004; Persons et 
al., 2003; Persons et al., 2004; Ragg et al., 2000; Sawai et al., 2003; Sawai et al., 2001) In 
regards to modeling of this approach with human HSPCs, we and others previously 
demonstrated that MGMTP140K-transduced SCID-repopulating cells and their progeny could 
be selected in vivo in NOD/SCID mice. (Pollok et al., 2003; Zielske et al., 2003) Human 
HSPCs derived from umbilical cord blood (UCB) or granulocyte colony-stimulating factor -
mobilized peripheral blood (MPB) that expressed MGMTP140K could be selected in vivo by 
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nonmyeloablative doses of O6-BG and BCNU.  Gerson and colleagues also reported similar 
results using MGMTP140K-transduced UCB in the NOD/SCID xenograft model. (Zielske et 
al., 2003) Additionally, our laboratory went on to investigate the extent to which 
MGMTP140K-transduced human SCID-repopulating cells and progeny could be protected in 
vivo by MGMTP140Kexpression during delivery of high-dose alkylator therapy administered 
that kills cancer cells. In this study, we compared the outcome of administering a low-dose 
O6-BG /BCNU regimen versus a high-dose regimen in NOD/SCID mice transplanted with 
MGMTP140K-transduced mobilized peripheral blood CD34+ cells. We found that, at least in 
the NOD/SCID xenograft model, when human MPB were transduced with an 
oncoretroviral vector that expresses MGMTP140K, only low numbers of human MPB cells 
were protected following delivery of the myeloablative regimen and that these cells were 
limited to mature lymphoid and myeloid cells. (Cai et al., 2006) In all these studies, 
NOD/SCID mice were used and analysis of long-term reconstitution in secondary recipient 
mice was not determined. We recently determined to what degree long-term human SCID-
repopulating cells could be selected in vivo by alkylator therapy and to compare the levels of 
selection in primary and secondary NOD/SCID and NSG mice. Our data demonstrate that 
human hematopoietic cells of multiple lineages were capable of expressing MGMTP140K for 
at least 4 months in primary recipients and in vivo-selected populations while not as robust 
as non-selected populations, were able to home and engraft in the bone marrow of 
secondary recipient NSG months for at least an additional 2 months.  In contrast to the 
NOD/SCID xenograft model, the NSG bone-marrow microenvironment appears to allow 
for optimal reconstitution and feasibility of long-term follow up of human 
hematopoiesis(Cai, 2011). The SCID-repopulating assay, while not perfect, does provide an 
opportunity for testing and refining clinically promising gene-transfer vectors and ex vivo 
transduction conditions. However, the downside is that while SCID-repopulating cells can 
be transduced with retroviral vectors, lack of correlation with the levels of gene marking in 
large animal studies and human gene therapy trials is the reality (Horn et al., 2003; 
Mezquita et al., 2008).  
7.3 In vivo selection of chemoresistant HSPCs in large animal models 
Achieving high transduction levels in HSPCs using large animal models has been 
challenging and hence, these may be the models that most closely simulate the low 
transduction rates observed in human gene-therapy trials to date (Bodine et al., 1993; Kiem 
et al., 1996b; Kiem et al., 1997b).   While this model can be expensive, meaningful numbers 
of dogs can generally be studied and data obtained more closely represents what may be 
expected in the human situation than studies conducted in mice or humanized mouse 
models. (Suter et al., 2004). Additionally, since the dog leukocyte antigen type I and II loci 
are fully characterized, this provides the opportunity to evaluate gene-therapy based 
approaches in an allogeneic transplantation setting (Ladiges et al., 1990; Maris & Storb, 2002; 
Nyberg et al., 2004; Suter et al., 2004; Venkataraman et al., 2007; Wagner et al., 1999). Due to 
the clinical applicability of the results obtained in the dog model,  a large amount of effort 
has been devoted to optimizing the conditions in the dog model which include optimizing 
the procedures to mobilize HSCs, culture these cells ex vivo, as well as transduce them with 
retroviral vectors and achieve efficient engraftment in vivo(Goerner et al., 1999; Goerner et 
al., 2001; Horn et al., 2004a; Kiem et al., 2007; Kiem et al., 1996a; Kiem et al., 1999). In terms 
long-term primary and secondary transplantation studies in canines, more than 80% of the 
granulocytes can now be marked by in vivo selection of cells expressing the MGMTP140K 
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(Beard et al., 2009; Neff et al., 2005). However, it is critical that some studies be performed in 
nonhuman primates since the hematopoietic cells derived from nonhuman primates can 
interact and respond to many of the human cytokines used for mobilization of HSCs as well 
as for transduction protocols. The availability of the macaque SHIV (simian–human 
immunodeficiency virus) model, that can be used to test gene-therapy strategies for 
acquired immunodeficiency syndrome (AIDS) is a clear advantage.(Joag, 2000; Trobridge & 
Kiem, 2010). Additionally in terms of long-term monitoring of animals transplanted with 
transduced cells, the relative similarity of the human genome to the genome of the 
nonhuman primates is most likely a highly relevant model for investigating retroviral-
insertions sites and monitoring for retroviral-mediated insertional mutagenesis (Calmels et 
al., 2005).  
The use of nonhuman primates to simulate potential outcomes in human gene therapy trials 
continues to develop. It is likely that the number of transduced cells will need to be 
expanded in diseases in which there is not an intrinsic growth advantage in diseases such as 
thalassemia and other hemoglobinopathies as well as expansion of cells that express anti-
HIV transgenes. A recent report of selection in rhesus macaques resulted in only transient 
selection in vivo(Larochelle et al., 2009), but efficient and stable long-term selection of  >60% 
in the pigtailed macaque using lentiviral vectors and 80% in the baboon model using 
gamma-retroviral vectors have been obtained(Trobridge & Kiem, 2010) Beard and 
colleagues show convincing data that MGMTP140K-trasnduced HSPCs of multiple lineages 
could be selected in vivo in both macaques and baboon nonhuman primates. Animals with 
different levels of base-line engraftment were all efficiently selected with a combination of 
O6-BG and BCNU and selection of transduced cells was sustained over time. With over 2 
years of follow up in some animals, there have been no signs of clonal emergence or 
hematopoietic malignancy. Detailed analysis of retroviral integration sites indicated the 
presence of multiple clones(Beard et al., 2010). One critical difference in these two studies 
showing transient versus sustained in vivo selection in the nonhuman primate models was 
that animals with the stable increases in selected cells had higher marking levels before 
initiating treatment with O6-BG and the alkylating agent.  
8. Genotoxicity concerns for in-vivo selection, retroviral-vector integration 
and potential mutagenicity of alkylator regimens 
All retroviral vectors will stably integrate into the genome of the host. Depending on where 
the vector integrates, its proximal integration near promoters of genes could cause increased 
activation of proto-oncogenes, inactivation of tumor suppressor genes, or modulate 
expression of genes that do not lead to noticeable changes in cellular metabolism and 
growth. The risk of biologically relevant proviral-mediated insertional oncogenesis has been 
previously documented (Baum et al., 2003).  As mentioned previously, the most publicized 
adverse event due to insertional mutagenesis was documented in the X-SCID trial and was 
predominantly caused by dysregulated expression of the LMO2 proto-oncogene (Baum et 
al., 2003; Baum et al., 2006; Ferguson et al., 2005; Hacein-Bey-Abina et al., 2003b; Williams & 
Baum, 2003).  Following the reports that retroviral-insertional mutagenesis was directly 
linked to the clonal expansion that caused leukemia in the French X-linked SCID gene 
therapy trial(Hacein-Bey-Abina et al., 2003b), a comprehensive study of large animals that 
had been previously transplanted with gamma-retroviral-transduced HSCs was conducted 
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(Kiem et al., 2004). In rhesus macaques, baboons, and dogs that had high levels of marked 
hematopoietic cells, oligoclonal or monoclonal expansion was not evident. However, at ~5 
years post-transplantation, in one rhesus macaque transplanted with gamma-retroviral 
vector-transduced CD34+ cells acute myeloid leukemia did develop (Seggewiss et al., 2006). 
Analysis of the leukemic cells tumor showed two clonal retroviral-vector insertions one of 
which was located near the anti-apoptotic gene, BCL2-A1.  It is important to note that the X-
SCID disease itself could also be an underlying factor that contributed to the 
leukemogenesis observed in some patients in the X-SCID trial.  
O6-methylating and chloroethylating agents such as TMZ and BCNU (Debiak et al., 2004; 
Hong et al., 1999; Kaina et al., 2001; Roos et al., 2007; Sanada et al., 2004) place an alkyl lesion 
at the O6 position of guanine. The O6-alkylguanine adducts can be highly mutagenic and 
cause cell death. The mechanisms by which O6-methylating agents, such as TMZ, is via 
futile cycles of mismatch repair pathway which ultimately lead to double-strand DNA 
breaks. For the chloroethylating agents, a variety of intracellular mechanisms can lead to cell 
death; the major toxicity is through the creation of interstrand DNA cross-links that block 
replication (Gerson, 2004; Kaina, 2004; Margison et al., 2002; Rasouli-Nia et al., 1994). The 
formation of chloroethyl and methyl lesions at the O6 position of guanine by alkylating 
agents are highly toxic to cells. In addition, other DNA alkyl adducts formed by exposure to 
these drugs, actually represent the vast majority of the adducts-N3 position of adenine; N7 
position of guanine; O2 position of thymine and O4 position of thymine(Gerson, 2004). The 
long-term impact of these lesions if left unrepaired is not known but clearly has the potential 
to lead to genome instability and subsequent emergence of transformed cells. A malignant 
phenotype has been described for some of these adducts in cell lines and rodent 
tissues(Maher et al., 1990; Sukumar & Barbacid, 1990; Vogel et al., 1996). While this is still an 
area of active investigation, there is no evidence to date that overexpression of mutant forms 
of MGMT and exposure to alkylating agents can lead to leukemia. To this end, several 
groups have demonstrated that hematopoietic cells transduced with retroviral vectors that 
express MGMTmutant proteins do not show an increased in the frequency of mutations or 
chromosomal aberrations upon challenge with O6 alkylating agents(Allay et al., 1997; 
Chinnasamy et al., 1998a; Chinnasamy et al., 1998b; Dumenco et al., 1993; Fairbairn et al., 
2000; Liu et al., 1994; Liu et al., 1999; Reese et al., 2001). Additionally, there have been no 
signs of hematopoietic clonal expansion in a canine large animal model in which animals 
transplanted animals MGMTP140K-transduced cells received alkylator therapy over a 
prolonged time period that also included some escalation in alkylator dose. There was a 
significant selection of the transduced cells over time, but whether dosing levels were 
indeed high enough to push the envelope on creating a mutagenic event in the genome and 
whether the regimen reached the dose range required to kill cancer cells is not clear at this 
time. (Neff et al., 2005). At least in the canines analyzed so far in which up to a 3-year follow 
up has been completed, there were no signs of mono- or oligo-clonal hematopoiesis or full 
blown leukemia in animals that underwent the MGMTP140K-dependent in vivo 
chemoselection. (Neff et al., 2006; Neff et al., 2005).  In a rhesus macaque that was 
transplanted with DHFR-transduced cells and underwent an anti-folate in-vivo selection 
regimen, an acute leukemia emerged at  5 years post-transplant and 3 years post-selection.  
(Seggewiss et al., 2006).  Two proviral insertions were found in the leukemic clone; one of 
the insertion sites was located near the anti-apoptotic gene BCL2-A1. Investigation and 
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testing in large animal models over a prolonged time period will be able to uncover whether 
potential toxicities linked to a particular transduction and/or chemoselection approach will 
yield clinically relevant information. 
9. Conclusions 
The potential for in vivo selection-induced stem-cell exhaustion does remain a concern. The use 
of small molecule MGMT inhibitors in combination with alkylating agents represent the most 
potent in vivo selection regimen characterized in all animal models studied to date. (Hobin & 
Fairbairn, 2002; Sawai et al., 2003). Due to the alkylator-mediated death and loss of 
hematopoietic cells that do not express the MGMT transgene, as well as the immense pressure 
that is placed on the MGMTP140K-expressing cells to repopulate the marrow, these populations 
are forced to undergo extreme degrees of expansion.  At what point the gene-modified HSC 
can no longer self-renew and undergo exhaustion and depletion is not clear. While we and 
others have demonstrated that O6-BG-resistant MGMT-transduced human CD34+ cells can be 
selected in vivo, the dose level and number of cycles could be critical factors that will tip the 
balance between adequate self-renewal and re-population versus stem-cell exhaustion and 
subsequent bone-marrow failure. While human CD34+ cells could be selected in vivo using 
chemoselection, a high-dose O6-BG/BCNU regimen appeared to result in a loss of transduced 
primitive human cells in the NOD-SCID xenograft model (Cai et al., 2006; Cai et al., 2011; 
Pollok et al., 2003). Our work clearly highlights the need to further define whether in vivo 
selection regimens place a detrimental proliferative stress on transduced HSPCs. (Neff et al., 
2006; Neff et al., 2005). The result of using myeloablative alkylator regimens which would be 
required in a cancer therapy setting will require further investigations in large animal models 
to determine the long-term efficacy and safety of this approach. 
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